- Datum28.10.2025
- Uhrzeit18:00 - 19:00 Uhr
- Veranstalter
stock3
Enanta Pharmaceuticals Inc. Chart

Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren

Enanta Pharmaceuticals Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,72 %
Intraday
-6,24 %
1 Woche
48,81 %
1 Monat
85,57 %
Seit Jahresbeginn
-16,31 %
1 Jahr
-77,11 %
3 Jahre
-75,69 %
5 Jahre
-55,56 %
10 Jahre
Passender Service zu Enanta Pharmaceuticals Inc.
Webinar zu Enanta Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)4,090-15,340
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Enanta Pharmaceuticals Inc.
Keine Dividenden verfügbar
Termine von Enanta Pharmaceuticals Inc.
- Nov17Enanta Pharmaceuticals Inc.Q4 2025 Earnings Release
- Feb10Enanta Pharmaceuticals Inc.Q1 2026 Earnings Release
- Mai11Enanta Pharmaceuticals Inc.Q2 2026 Earnings Release
Beschreibung
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
